ENTPD2 and COVID-19: Furthermore, this study reports markers including ADA, BTC, DPP6, EDIL3, LIF, ENTPD2, Flt3L, and LRP1 to be upregulated in severe COVID-19 patients; hence, they are proposed as novel biomarkers for severe cases of COVID-19.